While the glioma cells appeared to differentiate in response to retinoid treatment27, a lack of degradation of RARA in response to RA treatment would indicate a defect in protein turnover and RARA transcriptional function rather than constitutive activity. This evidence concerns the gene RARA and central nervous system cancer.